Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature

International Journal of Rheumatology

Volumn 2011, Issue , 2011, Pages

  Benucci, Maurizio ^a   Saviola, Gianantonio ^b   Manfredi, Mariangela ^a   Sarzi Puttini, Piercarlo ^c   Atzeni, Fabiola ^c,d  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE;

COMBINATION CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; HUMAN; MONOTHERAPY; ONSET AGE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84855585686     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2011/845496     Document Type: Review

References (32)

1. Salaffi F., De Angelis R., Grassi W., Marche Pain Prevalence; Investigation Group (MAPPING) study Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study Clinical and Experimental Rheumatology 2005 23 819 828 (Pubitemid 43040510)
2. Leardini G., Salaffi F., Montanelli R., Gerzeli S., Canesi B., A multicenter cost-of-illness study on rheumatoid arthritis in Italy Clinical and Experimental Rheumatology 2002 20 4 505 515 (Pubitemid 34846625)
3. Kvien T. K., Epidemiology and burden of illness of rheumatoid arthritis PharmacoEconomics 2004 22 2, supplement 1 1 12 (Pubitemid 38269929)
4. Kobelt G., Jnsson L., Lindgren P., Young A., Eberhardt K., Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis Arthritis and Rheumatism 2002 46 9 2310 2319
5. Fries J. F., Spitz P., Kraines R. G., Holman H. R., Measurement of patient outcome in arthritis Arthritis and Rheumatism 1980 23 2 137 145 (Pubitemid 10164318)
6. Torrance G. W., Measurement of health state utilities for economic appraisal: a review Journal of Health Economics 1986 5 1 1 30 (Pubitemid 16098443)
7. Della Rossa A., Neri R., Talarico R., Doveri M., Consensi A., Salvadori S., Lorenzoni V., Turchetti G., Bellelli S., Cazzato M., Bazzichi L., Monicelli P., Moscardini S., Bombardieri S., Diagnosis and referral of rheumatoid arthritis by primary care physician: results of a pilot study on the city of Pisa, Italy Clinical Rheumatology 2010 29 1 71 81
8. Myasoedova E., Crowson C. S., Kremers H. M., Therneau T. M., Gabriel S. E., Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 19552007 Arthritis and Rheumatism 2010 62 6 1576 1582
9. Benucci M., Cammelli E., Manfredi M., Saviola G., Baiardi P., Mannoni A., Early Rheumatoid Arthritis in Italy: study of incidence based on a two-level strategy in a sub-area of Florence (Scandicci-Le Signe) Rheumatology International 2008 28 8 777 781
10. Kobelt G., Kasteng F., Access to innovative trataments in rheumatoid arthritis in Italy. Chapter 3 Uptake of Biologic treatments pag 3.2, 2010
11. Gabriel S. E., Coyle D., Moreland L. W., A clinical and economic review of disease-modifying antirheumatic drugs PharmacoEconomics 2001 19 7 715 728 (Pubitemid 32664730)
12. Gyrd-Hansen D., Looking for willingness to pay (WTP) threshold for a QALYdoes it make sense? A critical view ISPOR Connection 2007 13 5 8
13. Anis A. H., Tugwell P. X., Wells G. A., Stewart D. G., A cost effectiveness analysis of cyclosporine in rheumatoid arthritis Journal of Rheumatology 1996 23 4 609 616 (Pubitemid 26132845)
14. Verhoeven A. C., Bibo J. C., Boers M., Engel G. L., van der Linden S., Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group British Journal of Rheumatology 1998 37 1102 1109
15. Maetzel A., Strand V., Tugwell P., Wells G., Bombardier C., Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis Arthritis Care and Research 2002 47 6 655 661 (Pubitemid 35461320)
16. Maetzel A., Strand V., Tugwell P., Wells G., Bombardier C., Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial PharmacoEconomics 2002 20 1 61 70 (Pubitemid 34155216)
17. Kobelt G., Lindgren P., Young A., Modelling the costs and effects of leflunomide in rheumatoid arthritis European Journal of Health Economics 2002 3 3 180 187 (Pubitemid 36402001)
18. Bruns A., Blss S., Hausdorf G., Burmester G. R., Hiepe F., A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis Arthritis and Rheumatism 2000 43 10 2316 2327
19. Choi H. K., Seeger J. D., Kuntz K. M., A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Journal of Rheumatology 2002 29 6 1156 1165 (Pubitemid 34601947)
20. Osiri M., Kamolratanakul P., Maetzel A., Tugwell P., Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis Rheumatology International 2007 27 11 1063 1069 (Pubitemid 47246587)
21. Schdlich P. K., Zeidler H., Zink A., Gromnica-Ihle E., Schneider M., Straub C., Brecht J. G., Huppertz E., Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs PharmacoEconomics 2005 23 4 377 393 (Pubitemid 40677055)
22. Korthals-De Bos I. B. C., Van Tulder M. W., Boers M., Verhoeven A. C., Adr H. J., Bibo J., Boonen A., Van Der Linden S. M. J. P., Indirect and total costs of early rheumatoid arthritis: A randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone Journal of Rheumatology 2004 31 9 1709 1716 (Pubitemid 39202509)
23. Hartman M., Van Ede A. E., Severens J. L., Laan R. F. J. M., Van De Putte L. B. A., Van Der Wilt G. J., Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis Journal of Rheumatology 2004 31 5 902 908 (Pubitemid 38585812)
24. Merkesdal S., Ruof J., Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis Zeitschrift fur Rheumatologie 2002 61 2 II29 II32
25. Scott D. L., Kingsley G., Clinical effectiveness of biologics in clinical practice Arthritis Research amp; Therapy 2010 23 115
26. Benucci M., Li Gobbi F., Sabadini L., Saviola G., Baiardi P., Manfredi M., The economic burden of biological therapy in rheumatoid arthritis in clinical practice: Cost-effectiveness analysis of sub-cutaneous anti-TNF treatment in italian patients International Journal of Immunopathology and Pharmacology 2009 22 4 1147 1152
27. Hewitson P. J., DeBroe S., McBride A., Milne R., Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications Journal of Clinical Pharmacy and Therapeutics 2000 25 4 295 302
28. Finckh A., Bansback N., Marra C. A., Anis A. H., Michaud K., Lubin S., White M., Sizto S., Liang M. H., Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis Annals of Internal Medicine 2009 151 9 612 621
29. Van Der Velde G., Pham B., MacHado M., Ieraci L., Witteman W., Bombardier C., Krahn M., Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review Arthritis Care and Research 2011 63 1 65 78
30. Schoels M., Wong J., Scott D. L., Zink A., Richards P., Landewé R., Smolen J. S., Aletaha D., Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis Annals of the Rheumatic Diseases 2010 69 6 995 1003
31. Rau R., Efficacy of methotrexate in comparison to biologies in rheumatoid arthritis Clinical and Experimental Rheumatology 2010 28 5, supplement 61 S58 S64
32. Schipper L. G., Kievit W., den Broeder A. A., van der Laar M. A., Adang E. M.M., Fransen J., van Riel P. L.C.M., Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective Rheumatology 2011 50 7 1320 1330